ClinicalTrials.gg
CompletedNCT03984214Updated Apr 10, 2025

Efficacy and Safety of Dronabinol in the Improvement of Chemotherapy-induced and Tumor-related Symptoms in Advanced Pancreatic Cancer

A Phase 3 interventional study of Dronabinol in Oral Dosage Form and Placebo in Oral Dosage Form in Pancreatic Cancer Non-resectable, Chemotherapy-induced Nausea and Vomiting and Pancreatic Cancer Metastatic, sponsored by Arbeitsgemeinschaft medikamentoese Tumortherapie. Completed at 11 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-04-10.

Sponsored by Arbeitsgemeinschaft medikamentoese Tumortherapie · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
109
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Aim of this phase III trial is to investigate the efficacy and safety of dronabinol (orally administered tetrahydrocannabinol (THC)) as adjuvant therapy to first-line standard chemotherapy in patients with metastatic pancreatic cancer for improvement of chemotherapy- and tumor-related symptoms applicated by individual titration up to the maximum tolerated dose.

Read the detailed description

Patients with pancreatic cancer suffer from multiple symptoms related to the tumor itself or induced by the chemotherapy. The available supportive therapy is still not able to relief all symptoms that are caused by the malignancy itself as well as by the antineoplastic therapy.

Additionally, anorexia and weight loss, that often result in increased morbidity and mortality in this patient population as well as in psycho-social burden and suffering in patients and their relatives, are unmet needs in pancreatic cancer patients.

Therapeutic approaches focus on treating the malignancy itself, additional nutritional support and physical examination might prevent patients from further side effects such as sarcopenia.

During the last decades a number of appetite-modulating drugs have been under clinical investigation. A number of studies focused on the endocannabinoid system, which is involved amongst others in appetite-modulating, antiemetic, analgesic and anti-inflammatory processes.

As dronabinol is already used as magistral formulation, its beneficial effect has often been observed in these patients in the clinical routine, especially in patients with therapy-refractory nausea and emesis. Due to its broad efficacy it might be of benefit for patients suffering from malignancy. Thus, investigators want to evaluate the efficacy of dronabinol in the improvement of chemotherapy-induced and tumor-related symptoms in advanced pancreatic patients during systemic first-line chemotherapy. However, data on optimal dosage are conflicting yet.

In detail, investigators want to study whether dronabinol has a positive influence on quality of life and whether symptoms caused by the tumor or by the chemotherapy itself might be palliated by dronabinol. Beneficial and potential harmful side effects and the personal perception of advanced pancreatic cancer patients will be documented.

02

Conditions studied

  • Pancreatic Cancer Non-resectable
  • Chemotherapy-induced Nausea and Vomiting
  • Pancreatic Cancer Metastatic

Keywords

  • Dronabinol
  • THC
  • Placebo
  • Pancreatic Cancer
  • Chemotherapy-induced Nausea and Vomiting
  • Tumor related symptoms
  • Quality of life
  • EORTC QLQ-C30
  • FOLFIRINOX
  • Abraxane
  • Gemcitabine
03

In context

Vomiting

794 studies on the registry are indexed under Vomiting; 98 are open to participants now.

This study's enrollment of 109 is close to the median of 102 across 674 interventional studies indexed under Vomiting.

Browse Vomiting studies →

Lead sponsor

Arbeitsgemeinschaft medikamentoese Tumortherapie is the lead sponsor of 43 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female subjects aged ≥18
  • Patients with diagnosis of locally advanced, inoperable or pancreatic cancer, eligible for chemotherapy with FOLFIRINOX or gemcitabine+Abraxane®
  • According to investigator of > 4 months at screening
  • Female patients must either be or surgically sterilized or use a highly effective method of (hormonal contraceptives, intra-uterine devices, or diaphragms with spermicide) for the duration of the study and/or must have a negative pregnancy test (female patients with only)
  • Willing and able to provide written .
  • Written informed consent given prior to any trial-related procedure not part of the normal medical practice.

Exclusion criteria

Exclusion Criteria:

  • Patients who are members of the staff of the trial center, staff of the sponsor or CRO, the investigator him/herself or close relatives of the investigator.
  • Simultaneous participation in another interventional clinical trial, participation in another trial with less than 30 days or five half-lives of the IMP (whatever is longer) to screening, or previous participation in this trial.
  • Ineligible for chemotherapy treatment with FOLFIRINOX or gemcitabine+Abraxane®
  • Use of dronabinol or cannabis-based medicine with THC as constituent within 6 months before screening. A urine drug test will be performed during screening phase.
  • Use of marihuana within the last 4 weeks and unwillingness to abstain for the duration of the study. A urine drug test will be performed during screening phase.
  • Currently receiving chemotherapy or anticipated use of chemotherapy due to any condition not related to locally advanced or pancreatic cancer
  • History of or existing cardiac diseases or pathological findings (e.g. chronic insufficiency III/IV, severe arrhythmia, unstable angina pectoris, myocardial infarction within the past 6 months, significant -prolongation etc.), which in the opinion of the investigator might interfere with the safety or tolerability of the study treatment. An has to be done to exclude pathological findings and must not be older than 3 months before screening or if none is available, has to be performed during the screening phase and assessed prior to randomization
  • , severe pulmonary diseases, uncontrolled hypertension, or poorly controlled diabetes
  • History of or existing relevant CNS and/or psychiatric disorders (e.g. schizophrenia, psychosis, manic and/or depressive disorders, suicidal ideations, etc) which might interfere with the safety or tolerability of the study treatment. Patients with reactive depression are not excluded from participation.
  • Known current or past (within the last year prior to screening) alcohol, narcotics or drug abuse
  • Pregnancy or breast feeding
  • Known allergy to cannabinoids and other constituents of the medicinal product
  • Intake of prohibited concomitant medication
  • Any other substantial medical condition that in the opinion of the investigator could create undue risk to the subject or could affect adherence with the trial protocol
  • Legal incapacity, limited legal capacity or any other condition which makes the subject unable to understand the subject information and form (ICF)
  • Patients unable or unwilling to waive driving motor vehicles or using machines especially during titration period
  • Unable or unwilling to comply with the protocol regulations
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
109 participants (actual)

Study arms

  • Active comparator
    Dronabinol

    BX-1 contains 25 mg dronabinol/ml (2.5% delta-9-trans-tetrahydrocannabinol = THC), oral solution; three applications per day from 2.5 mg (3 x 1 droplet) up to 30 mg (3 x 12 droplets)

    Drug: Dronabinol in Oral Dosage Form

  • Placebo comparator
    Placebo

    Placebo: oral solution with cannabis flavor without active substance and otherwise identical to active comparator, three applications per day from 3 x 1 droplet up to 3 x 12 droplets

    Drug: Placebo in Oral Dosage Form

Interventions

  • DrugDronabinol in Oral Dosage Form

    Titration period for 4 weeks: titration according to tolerability from 2.5 mg (3 x 1 droplet) up to 30 mg (3 x 12 droplets) per day; dose increased by 2.5 mg (3 x 1 droplet) every other day Maintenance period for 12 weeks: individually tolerated maximum dose (up to 30 mg ≙ 3 x 12 droplets) at end of titration period will be continued for maintenance treatment Tapering period for 2 weeks: dose is decreased every other day by 5 mg (3 x 2 droplets) Safety follow-up: 4 weeks after end of treatment

    Also known as: BX-1

  • DrugPlacebo in Oral Dosage Form

    Titration period for 4 weeks: titration according to tolerability from 3 x 1 droplet up to 3 x 12 droplets per day; dose increased by 3 x 1 droplet every other day Maintenance period for 12 weeks: individually tolerated maximum dose (up to 3 x 12 droplets) at end of titration period will be continued for maintenance treatment Tapering period for 2 weeks: dose is decreased every other day by 3 x 2 droplets Safety follow-up: 4 weeks after end of treatment

06

What researchers measure

Primary outcomes

  1. Standardized area under the curve of the European Organisation for Research and Treatment of Cancer (EORTC) quality of life questionnaire (QLQ)-C30 symptom summary score over the on-treatment period.

    The EORTC-QLQ-C30 is an integrated system for assessing the health-related quality of life (QoL) of cancer patients participating in international clinical trials. The validated QLQ-C30 summary score is calculated as mean score of the 13 of the 15 EORTC QLQ-C30 scales (v3.0), based on 27 of 30 items (the Financial Impact scale and Quality of Life score are not included). A high score for a symptom scale / item (fatigue, nausea and vomiting, pain, dyspnoea, insomnia, appetite loss, constipation, diarrhoea) represents a high level of symptomatology / problems. A high score for a functional scale (physical functioning, role functioning, cognitive functioning, emotional functioning, social functioning) represents a high / healthy level of functioning. Scores for individual items: "Not at All" = 1 point, "A Little" = 2 points, "Quite a Bit" = 3 points, "Very Much" = 4 points. A linear transformation is used to standardize the raw score, so that overall scores range from 0 to 100.

    Time frame: Prior to treatment start until end of 16 weeks maintenance treatment

Secondary outcomes

  1. Standardized area under the curve of the European Organisation for Research and Treatment of Cancer (EORTC) quality of life questionnaire (QLQ)-C30 symptom summary score over the maintenance period

    The European Organisation for Research and Treatment of Cancer (EORTC) quality of life questionnaire (QLQ) is an integrated system for assessing the health-related quality of life (QoL) of cancer patients participating in international clinical trials. The validated QLQ-C30 summary score is calculated as mean score of items. A high score for a symptom scale / item (fatigue, nausea and vomiting, pain, dyspnoea, insomnia, appetite loss, constipation, diarrhoea) represents a high level of symptomatology / problems. Scores for individual items: "Not at All" = 1 point, "A Little" = 2 points, "Quite a Bit" = 3 points, "Very Much" = 4 points. A linear transformation is used to standardize the raw score, so that overall scores range from 0 to 100.

    Time frame: After 4 weeks of treatment until week 16

  2. Change of European Organisation for Research and Treatment of Cancer (EORTC) quality of life questionnaire (QLQ)-C30 symptom summary score from baseline to summary score over the maintenance period

    The European Organisation for Research and Treatment of Cancer (EORTC) quality of life questionnaire (QLQ) is an integrated system for assessing the health-related quality of life (QoL) of cancer patients participating in international clinical trials. The validated QLQ-C30 summary score is calculated as mean score of items. A high score for a symptom scale / item (fatigue, nausea and vomiting, pain, dyspnoea, insomnia, appetite loss, constipation, diarrhoea) represents a high level of symptomatology / problems. Scores for individual items: "Not at All" = 1 point, "A Little" = 2 points, "Quite a Bit" = 3 points, "Very Much" = 4 points. A linear transformation is used to standardize the raw score, so that overall scores range from 0 to 100.

    Time frame: From treatment start until week 16

  3. Symptom scales of European Organisation for Research and Treatment of Cancer (EORTC) quality of life questionnaire (QLQ)-C30

    A high score for a symptom scale / item (fatigue, nausea and vomiting, pain, dyspnoea, insomnia, appetite loss, constipation, diarrhoea) represents a high level of symptomatology / problems. Scores for individual items: "Not at All" = 1 point, "A Little" = 2 points, "Quite a Bit" = 3 points, "Very Much" = 4 points. A linear transformation is used to standardize the raw score, so that overall scores range from 0 to 100.

    Time frame: At baseline and 2-weekly until end of treatment at week 18

  4. Global quality of life of the European Organisation for Research and Treatment of Cancer (EORTC) quality of life questionnaire (QLQ)-C30

    The European Organisation for Research and Treatment of Cancer (EORTC) quality of life questionnaire (QLQ) is an integrated system for assessing the health-related quality of life (QoL) of cancer patients participating in international clinical trials. The validated QLQ-C30 summary score is calculated as mean score of items. A high score for the global health status (overall health during the past week) and global QoL (overall quality of life during the past week) represents a high QoL. Scores: 1 - 7, 1 = very poor and 7 = excellent. A linear transformation is used to standardize the raw score, so that overall scores range from 0 to 100.

    Time frame: At baseline and 2-weekly until end of treatment at week 18

  5. Functional scales of the European Organisation for Research and Treatment of Cancer (EORTC) quality of life questionnaire (QLQ)-C30

    The European Organisation for Research and Treatment of Cancer (EORTC) quality of life questionnaire (QLQ) is an integrated system for assessing the health-related quality of life (QoL) of cancer patients participating in international clinical trials. A high score for a functional scale (physical functioning, role functioning, cognitive functioning, emotional functioning, social functioning) represents a high / healthy level of functioning. Scores for individual items: "Not at All" = 1 point, "A Little" = 2 points, "Quite a Bit" = 3 points, "Very Much" = 4 points. A linear transformation is used to standardize the raw score, so that overall scores range from 0 to 100.

    Time frame: At baseline and 2-weekly until end of treatment at week 18

  6. Mean change from baseline of the Glasgow Prognostic Score

    Change of serum levels of the score-defining biomarkers C-reactive protein (CRP) and albumin. Prognostic scores; 0 (CRP ≥ 10 mg/l), 1 (CRP \> 10 mg/l and albumin ≥ 35 g/l), 2 CRP \> 10 mg/l and albumin \< 35g/l). Score 0 indicates good prognosis, score 1 intermediate prognosis and score 2 poor prognosis.

    Time frame: At baseline and at end of treatment at week 16

  7. Amount of concomitant medication taken

    Special focus on antiemetic, psychotropic and pain medication

    Time frame: From baseline until end of treatment at week 18

  8. Mean time to critical weight-loss (5%)

    Assessed with a standard scale

    Time frame: From baseline until end of treatment at week 16

  9. Mean changes from baseline for Bioelectrical Impedance Analysis (BIA) parameter Lean body mass (LBM)

    Mean change of Lean body mass (LBM = Fat free mass FFM) kg

    Time frame: At baseline and at end of treatment at week 16

  10. Mean changes from baseline for Bioelectrical Impedance Analysis (BIA) parameter Total body water (TBW)

    Mean change of Total body water (TBW) kg

    Time frame: At baseline and at end of treatment at week 16

  11. Mean changes from baseline for Bioelectrical Impedance Analysis (BIA) parameter Fat mass (FM)

    Mean change of Fat mass (FM) kg

    Time frame: At baseline and at end of treatment at week 16

  12. Mean changes from baseline for Bioelectrical Impedance Analysis (BIA) parameter Body cell mass (BCM)

    Mean change of Body cell mass (BCM) kg

    Time frame: At baseline and at end of treatment at week 16

  13. Mean changes from baseline for Bioelectrical Impedance Analysis (BIA) parameter Extracellular mass (EM)

    Mean change of Extracellular mass (ECM) kg

    Time frame: At baseline and at end of treatment at week 16

  14. Mean changes from baseline for Bioelectrical Impedance Analysis (BIA) parameter Phase angle (PA)

    Mean change of Phase angle (PA); Phase Angle has long been linked to nutritional status. This marker is fast becoming recognised as a global health marker in total body health assessment. A higher Phase Angle could mean an increase in muscle mass (body cell mass) or a decrease in fluid, either from recovery from infection or injury (a good thing!) or a decrease in fluid from dehydration (a bad thing!). A loss of fat could also increase Phase Angle. A lower Phase Angle could mean a loss of muscle mass (a bad thing), or an increase of fluid (rehydrating which is a good thing, or sign of inflammation or infection - a bad thing), or gaining fat (which could be a good or bad thing depending on your state of health). Phase Angle is a direct measurement, (not a calculation using equations) of the cell membrane.

    Time frame: At baseline and at end of treatment at week 16

  15. Mean changes from baseline for Bioelectrical Impedance Analysis (BIA) parameter Resistance (Rz)

    Mean change of Resistance (Rz), unit ohm; the resistance reflects the water or fluid in the body

    Time frame: At baseline and at end of treatment at week 16

  16. Mean changes from baseline for Bioelectrical Impedance Analysis (BIA) parameter Reactance(Xc)

    Mean change of Reactance (Xc), unit ohm; reactance reflects the body cell mass.

    Time frame: At baseline and at end of treatment at week 16

  17. Mean change from baseline of muscle strength

    To assess physical strength of patient's handgrip strength will be measured prior and after study treatment using a hydraulic hand dynamometer; mean value of three consecutive measurements will be documented

    Time frame: At baseline and at end of treatment at week 16

  18. Proportion of patients not adhering to individual baseline chemotherapy regimen

    Percentage of patients who do not receive full dose of planned chemotherapy regimen and/or within scheduled time frame (interruption or delay)

    Time frame: From baseline until end of treatment at week 18

  19. Chemotherapeutic dose intensity over the treatment period of 18 weeks

    The total amount of applied chemotherapy over the study treatment phase is documented

    Time frame: From baseline until end of treatment at week 18

  20. Frequency and severity of (serious) adverse events (S)AE

    Assessed with Common Terminology Criteria for Adverse Events (NCI-CTCAE V5.0)

    Time frame: From baseline until safety visit at week 22

  21. Incidence of adverse drug reactions (ARs)

    Frequency and severity of ARs

    Time frame: From baseline until safety visit at week 22

  22. Progression-free survival (PFS)

    PFS in months; ; patients will be asked to agree on collection of data regarding PFS also after end of trial

    Time frame: From treatment start until the date of first documented progression or death from any cause assessed up to week 22

  23. Overall survival (OS)

    OS in months; ; patients will be asked to agree on collection of data regarding PFS also after end of trial

    Time frame: From treatment start until death from any cause assessed up to week 22

07

Study locations

11 sites
  • Klinikum Wels-Grieskirchen GmbH, Abteilung für Innere Medizin IV
    Wels, Oberösterreich 4600, Austria
  • KABEG-Klinikum Klagenfurt am Woerthersee, Abteilung f. Anaesthesie u. Intensivmedizin
    Klagenfurt, 9020, Austria
  • LKH Hochsteiermark - Standort Leoben Abteilung für Innere Medizin und Hämatologie und internistische Onkologie
    Leoben, 8700, Austria
  • IIIrd Medical Department, Private Medical University Hospital Salzburg
    Salzburg, 5020, Austria
  • Krankenhaus d. Barmherzigen Brüder, Abt. f. Innere Medizin
    St. Veit an der Glan, 9300, Austria
  • Pyhrn-Eisenwurzen Klinikum Steyr, Interne Medizin II
    Steyr, A-4400, Austria
  • Hanusch Krankenhaus der Wiener Gebietskrankenkasse
    Vienna, 1140, Austria
  • KH Zams, Innere Medizin, Internistische Onkologie u. Haematologie
    Zams, 6511, Austria
  • Universitätsmedizin Göttingen Abt. f. Gastroenterologie, gastrointestinale Onkologie u. Endokrinologie
    Göttingen, 37075, Germany
  • München Klinik Neuperlach
    München, 81737, Germany
  • Marienhospital Onkologie, Hämatologie, Palliativmedizin
    Stuttgart, 07199, Germany
08

References and documents

Publications

  • van Amerongen G, Kanhai K, Baakman AC, Heuberger J, Klaassen E, Beumer TL, Strijers RLM, Killestein J, van Gerven J, Cohen A, Groeneveld GJ. Effects on Spasticity and Neuropathic Pain of an Oral Formulation of Delta9-tetrahydrocannabinol in Patients WithProgressive Multiple Sclerosis. Clin Ther. 2018 Sep;40(9):1467-1482. doi: 10.1016/j.clinthera.2017.01.016. Epub 2017 Feb 9. PubMed 28189366 ↗
  • Davis MP. Cannabinoids for Symptom Management and Cancer Therapy: The Evidence. J Natl Compr Canc Netw. 2016 Jul;14(7):915-22. doi: 10.6004/jnccn.2016.0094. PubMed 27407130 ↗
  • Cannabis-In-Cachexia-Study-Group; Strasser F, Luftner D, Possinger K, Ernst G, Ruhstaller T, Meissner W, Ko YD, Schnelle M, Reif M, Cerny T. Comparison of orally administered cannabis extract and delta-9-tetrahydrocannabinol in treating patients with cancer-related anorexia-cachexia syndrome: a multicenter, phase III, randomized, double-blind, placebo-controlled clinical trial from the Cannabis-In-Cachexia-Study-Group. J Clin Oncol. 2006 Jul 20;24(21):3394-400. doi: 10.1200/JCO.2005.05.1847. PubMed 16849753 ↗
  • Turgeman I, Bar-Sela G. Cannabis Use in Palliative Oncology: A Review of the Evidence for Popular Indications. Isr Med Assoc J. 2017 Feb;19(2):85-88. PubMed 28457056 ↗
  • Jatoi A, Windschitl HE, Loprinzi CL, Sloan JA, Dakhil SR, Mailliard JA, Pundaleeka S, Kardinal CG, Fitch TR, Krook JE, Novotny PJ, Christensen B. Dronabinol versus megestrol acetate versus combination therapy for cancer-associated anorexia: a North Central Cancer Treatment Group study. J Clin Oncol. 2002 Jan 15;20(2):567-73. doi: 10.1200/JCO.2002.20.2.567. PubMed 11786587 ↗

Related links

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2019 to primary completion in Sep 2024, 57 months.

Of 37 non-industry phase 3 interventional studies under Vomiting, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 51. This study's 57 months is above that.

Counting every sponsor, half of 56 studies reached it within 21 months; a quarter within 12 and three quarters within 38.

How these figures are worked out, and which studies are left out of them.

Registered
May 28, 2019
First posted
Jun 12, 2019
StartActual
Dec 16, 2019
Primary completionActual
Sep 25, 2024
CompletionActual
Sep 25, 2024
Last update
Apr 10, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 10, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03984214
Lead sponsor
Arbeitsgemeinschaft medikamentoese Tumortherapie
Collaborators
Medical University of Graz, Unidata Geodesign, Bionorica SE
Responsible party
Sponsor
First posted
Jun 12, 2019
Start date
Dec 16, 2019
Primary completion
Sep 25, 2024
Completion
Sep 25, 2024
Last update
Apr 10, 2025

Study contacts

Felix Keil, Prof.MD
principal investigator · Med. Dept. III, Hematolog and Oncology

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion